Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | May 31, 2022 | June 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date May 31, 2022 · Filed June 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2032-05-31 | Direct | 4,400 |
Reported balance
After 2022-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-31 · Grant · Acquired 4,400 · Balance 4,400 F1: The options vest 100% on the earlier of May 31, 2023 or the date immediately prior to the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the earlier of May 31, 2023 or the date immediately prior to the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acer Therapeutics Inc.
Report date November 17, 2023 · Filed November 20, 2023
Section 16 reporting ended · disclosed 2023-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-17 transaction · row 1
1 source rowRow 1 · 2023-11-17 · Disposition to issuer · Disposed 14,285 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra.
F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company.
F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2023 Filed Nov 20, 2023 17:05 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | Disposition to issuerCommon Stock, $0.0001 par value per share | 14,285 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-020441 · doc4.xml · nonDerivative · entry 1 Joseph Donald · CIK 0001319460 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3 · kind: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3 · price: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:41 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001209191-23-019327 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Chief Legal Officer and Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option, which is made as part of the issuer's 2023 annual compensation cycle, vests and becomes exercisable over four years as follows: 25% of the shares vest on March 14, 2024, and the remaining 75% of the shares vest quarterly over the remaining three years. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 20:11 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 4,400 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-22-033137 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2032-05-31 F1 · derivative.exercise_date: The options vest 100% on the earlier of May 31, 2023 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:24 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001209191-22-003720 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Chief Legal Officer and Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years as follows: 25% of the shares vest on January 14, 2023, and the remaining 75% of the shares vest quarterly over the remaining three years. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:18 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $9.90 | $0.00 |
DisclosureSEC source: 0001209191-21-032331 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2031-05-11 F1 · derivative.exercise_date: The options vest 100% on the earlier of May 11, 2022 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 16:15 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001209191-21-004279 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Chief Legal Officer and Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-01-15 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years as follows: 25% of the shares vest on January 15, 2022, and the remaining 75% of the shares vest quarterly over the remaining three years. Read SEC document |
| July 24, 2020 Filed Jul 28, 2020 09:01 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 14,285 | $3.50 | $49,997.50 |
DisclosureSEC source: 0001209191-20-043803 · doc4.xml · nonDerivative · entry 1 Joseph Donald · CIK 0001319460 · Chief Legal Officer and Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,285 Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:04 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001209191-20-029145 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The options vest 100% on the earlier of May 12, 2021 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| September 18, 2019 Filed Sep 23, 2019 19:38 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001209191-19-050506 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Chief Legal Officer and Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-09-18 F1 · derivative.exercise_date: The option vests and becomes exercisable as follows: 50% on 01/01/2021 and 50% on 01/01/2022. Read SEC document |
| May 14, 2019 Filed May 15, 2019 20:43 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001209191-19-030043 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2029-05-14 F1 · derivative.exercise_date: The options vest 100% on the earlier of May 14, 2020 or the date immediately prior to the Issuer's next annual meeting of stockholders. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 13:57 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $24.46 | $0.00 |
DisclosureSEC source: 0001209191-19-007243 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Chief Legal Officer and Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years as follows: 25% of the shares vest on February 1, 2020, and 1/16th of the shares vest each quarter thereafter for the remaining three years. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:44 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001209191-18-051904 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The options vest in monthly installments over one year commencing one month from September 20 2018. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 16:32 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $18.53 | $0.00 |
DisclosureSEC source: 0001209191-18-025840 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Chief Legal Officer and Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-04-20 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years as follows: 25% of the shares vest on April 20, 2019, and the remaining 75% vesting quarterly over the remaining three years. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:49 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047584 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2027-08-01 F1 · derivative.exercise_date: The options vest in monthly installments over 36 months commencing one month from August 1, 2017. Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 19:09 UTC Amendment | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052393 · doc4a.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. F2 · derivative.exercise_date: The options vest in monthly installments over 36 months commencing one month from August 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.